Patent ID: 6686454
Filing Date: 2004-02-03
Classification: A61K,C07K,G01N,Y10S

Abstract:
An isolated antibody selected from the group consisting of CSA-2G9 produced by the hybridoma cell line deposited with ATCC as PTA-4170, AM1-7F5 produced by the hybridoma cell line deposited with ATCC as PTA-4142, AM1-3B1 produced by the hybridoma cell line deposited with ATCC as PTA-4154, AM1-2E10 produced by the hybridoma cell line deposited with ATCC as PTA-4141, AM9-1-3C1 produced by the hybridoma cell line deposited with ATCC as PTA-4155, AM19-1-5D2 produced by the hybridoma cell line deposited with ATCC as PTA-4163, AM19-1-5B3 produced by the hybridoma cell line deposited with ATCC as PTA-4147, AM19-9-5A6 produced by the hybridoma cell line deposited with ATCC as PTA-4150, AM9-1-6D4 produced by the hybridoma cell line deposited with ATCC as PTA-4157, AM9-1-7D2 produced by the hybridoma cell line deposited with ATCC as PTA-4144, AM9-9-11G9 produced by the hybridoma cell line deposited with ATCC as PTA-4158, AM9-9-6C3 produced by the hybridoma cell line deposited with ATCC as PTA-4146, AM19-1-7E12 produced by the hybridoma cell line deposited with ATCC as PTA-4161, AM9-1-2A11 produced by the hybridoma cell line deposited with ATCC as PTA-4143, AM19-9-1E11 produced by the hybridoma cell line deposited with ATCC as PTA-4149, AM19-9-1D8 produced by the hybridoma cell line deposited with ATCC as PTA-4148, AM19-9-2G9 produced by the hybridoma cell line deposited with ATCC as PTA-4160, AM9-9-11H11 produced by the hybridoma cell line deposited with ATCC as PTA-4159, AM9-9-4F5 produced by the hybridoma cell line deposited with ATCC as PTA-4145, and AM9-1-4D6 produced by the hybridoma cell line deposited with ATCC as PTA-4156.